Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H. Tsurutani J, et al. Among authors: sakata e. Breast. 2021 Feb;55:63-68. doi: 10.1016/j.breast.2020.12.002. Epub 2020 Dec 9. Breast. 2021. PMID: 33341707 Free PMC article. Clinical Trial.
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: sakata e. Breast Cancer. 2022 Jan;29(1):131-143. doi: 10.1007/s12282-021-01290-5. Epub 2021 Sep 7. Breast Cancer. 2022. PMID: 34491513 Free PMC article. Clinical Trial.
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: sakata e. Breast Cancer. 2022 Jan;29(1):186-188. doi: 10.1007/s12282-021-01296-z. Breast Cancer. 2022. PMID: 34562260 Free PMC article. No abstract available.
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Abe Y, Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F, Shien T, Doihara H, Toyooka S. Abe Y, et al. Among authors: sakata e. Acta Med Okayama. 2022 Dec;76(6):661-671. doi: 10.18926/AMO/64116. Acta Med Okayama. 2022. PMID: 36549768 Free article. Clinical Trial.
Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
Watanabe M, Fujiki S, Okura Y, Toshikawa C, Ikarashi M, Kanbayashi C, Kaneko K, Kikuchi A, Sakata E, Tsuchida K, Ozaki K, Moro K, Kubota N, Kashimura T, Moriyama M, Sato N, Tanabe N, Koyama Y, Wakai T, Saijo Y, Inomata T. Watanabe M, et al. Among authors: sakata e. Breast Cancer. 2024 Nov;31(6):1080-1091. doi: 10.1007/s12282-024-01623-0. Epub 2024 Aug 13. Breast Cancer. 2024. PMID: 39138789 Free PMC article.
163 results